SEC Company Response from Vincerx Pharma, Inc. (VINC) (CIK 0001796129) (VINC) — Mar 4, 2020
Vincerx Pharma, Inc. (VINC) (CIK 0001796129)
Date: March 4, 2020 · CIK: 0001796129 · Accession: 0001104659-20-029270
AI Filing Summary & Sentiment
Referenced dates: March 4, 2020
Letter
Via Edgar Re: LifeSci Acquisition Corp. Amendment No. 2 to Registration Statement on Form S-1 Filed March 3, 2020 CIK No. 0001796129
Dear Mr. Alper:
On behalf of our client, LifeSci Acquisition Corp. (the “Company”), we hereby provide a response to the comments issued in a letter dated March 4, 2020 (the “Staff’s Letter”) regarding Amendment No. 2 to the Company’s draft Registration Statement on Form S-1 (the “Registration Statement”). Contemporaneously, we are submitting the amended draft Registration Statement via Edgar (the “Amended S-1”).
In order to facilitate the review by the Commission’s staff (the “Staff”) of the Amended S-1, we have responded, on behalf of the Company, to the comments set forth in the Staff’s Letter on a point-by-point basis. The numbered paragraphs set forth below respond to the Staff’s comments and correspond to the numbered paragraph in the Staff’s Letter.
Los Angeles New York Chicago Nashville Washington, DC Beijing Hong Kong www.loeb.com
A limited liability partnership including professional corporations
Ronald Alper
March 4, 2020
Page 2
Form S-1/A
Exhibits
1. Please reconcile the exclusive forum provision in exhibit 3.2 with your disclosure on page 81 or advise.
Response: Exhibit 3.2 has been revised to conform to the disclosure on page 81 of the Registration Statement.
Please call me at 212 407-4866 if you would like additional information with respect to any of the foregoing. Thank you.
Sincerely,
/s/ Giovanni Caruso
Show Raw Text
CORRESP
1
filename1.htm
Giovanni Caruso
Partner
345 Park Avenue
New York, NY 10154
Direct 212.407.4866
Main 212.407.4000
Fax 212.937.3943
gcaruso@loeb.com
Via Edgar
March 4, 2020
Ronald Alper
U.S. Securities & Exchange Commission
100
F Street, NE
Washington, D.C. 20549
Re: LifeSci Acquisition Corp.
Amendment
No. 2 to Registration Statement on Form S-1
Filed
March 3, 2020
CIK
No. 0001796129
Dear Mr. Alper:
On behalf of our client, LifeSci Acquisition
Corp. (the “Company”), we hereby provide a response to the comments issued in a letter dated March 4, 2020 (the “Staff’s
Letter”) regarding Amendment No. 2 to the Company’s draft Registration Statement on Form S-1 (the “Registration
Statement”). Contemporaneously, we are submitting the amended draft Registration Statement via Edgar (the “Amended
S-1”).
In order to facilitate the review by the
Commission’s staff (the “Staff”) of the Amended S-1, we have responded, on behalf of the Company, to the comments
set forth in the Staff’s Letter on a point-by-point basis. The numbered paragraphs set forth below respond to the Staff’s
comments and correspond to the numbered paragraph in the Staff’s Letter.
Los Angeles
New York
Chicago
Nashville
Washington, DC
Beijing Hong Kong
www.loeb.com
A limited liability partnership
including professional corporations
Ronald
Alper
March 4, 2020
Page 2
Form S-1/A
Exhibits
1. Please
reconcile the exclusive forum provision in exhibit 3.2 with your disclosure on page 81 or advise.
Response: Exhibit
3.2 has been revised to conform to the disclosure on page 81 of the Registration Statement.
Please call me at 212
407-4866 if you would like additional information with respect to any of the foregoing. Thank you.
Sincerely,
/s/ Giovanni Caruso
Giovanni Caruso
Partner